These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 19037032)
1. Prevention of developmental delays in a Down syndrome mouse model. Toso L; Cameroni I; Roberson R; Abebe D; Bissell S; Spong CY Obstet Gynecol; 2008 Dec; 112(6):1242-1251. PubMed ID: 19037032 [TBL] [Abstract][Full Text] [Related]
2. Prenatal treatment prevents learning deficit in Down syndrome model. Incerti M; Horowitz K; Roberson R; Abebe D; Toso L; Caballero M; Spong CY PLoS One; 2012; 7(11):e50724. PubMed ID: 23209818 [TBL] [Abstract][Full Text] [Related]
3. Prevention of learning deficit in a Down syndrome model. Incerti M; Toso L; Vink J; Roberson R; Nold C; Abebe D; Spong CY Obstet Gynecol; 2011 Feb; 117(2 Pt 1):354-361. PubMed ID: 21252750 [TBL] [Abstract][Full Text] [Related]
4. Reversal of alcohol-induced learning deficits in the young adult in a model of fetal alcohol syndrome. Incerti M; Vink J; Roberson R; Wood L; Abebe D; Spong CY Obstet Gynecol; 2010 Feb; 115(2 Pt 1):350-356. PubMed ID: 20093910 [TBL] [Abstract][Full Text] [Related]
5. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737 [TBL] [Abstract][Full Text] [Related]
6. Protective peptides that are orally active and mechanistically nonchiral. Brenneman DE; Spong CY; Hauser JM; Abebe D; Pinhasov A; Golian T; Gozes I J Pharmacol Exp Ther; 2004 Jun; 309(3):1190-7. PubMed ID: 15007105 [TBL] [Abstract][Full Text] [Related]
7. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Kazim SF; Blanchard J; Bianchi R; Iqbal K Sci Rep; 2017 Apr; 7():45561. PubMed ID: 28368015 [TBL] [Abstract][Full Text] [Related]
8. Prevention of the alcohol-induced changes in brain-derived neurotrophic factor expression using neuroprotective peptides in a model of fetal alcohol syndrome. Incerti M; Vink J; Roberson R; Benassou I; Abebe D; Spong CY Am J Obstet Gynecol; 2010 May; 202(5):457.e1-4. PubMed ID: 20452488 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotective peptides prevent some alcohol-induced alteration in gamma-aminobutyric acid A-beta3, which plays a role in cleft lip and palate and learning in fetal alcohol syndrome. Toso L; Roberson R; Abebe D; Spong CY Am J Obstet Gynecol; 2007 Mar; 196(3):259.e1-5. PubMed ID: 17346546 [TBL] [Abstract][Full Text] [Related]
10. Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome. Adams AD; Hoffmann V; Koehly L; Guedj F; Bianchi DW Am J Obstet Gynecol; 2021 Sep; 225(3):296.e1-296.e13. PubMed ID: 33766516 [TBL] [Abstract][Full Text] [Related]
11. Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss. Zhou FC; Fang Y; Goodlett C Alcohol Clin Exp Res; 2008 Aug; 32(8):1361-71. PubMed ID: 18565153 [TBL] [Abstract][Full Text] [Related]
12. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Shiryaev N; Pikman R; Giladi E; Gozes I Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979 [TBL] [Abstract][Full Text] [Related]
13. Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. Sahir N; Brenneman DE; Hill JM J Mol Neurosci; 2006; 30(3):329-40. PubMed ID: 17401158 [TBL] [Abstract][Full Text] [Related]
14. Spatiotemporal development of spinal neuronal and glial populations in the Ts65Dn mouse model of Down syndrome. Aziz NM; Klein JA; Brady MR; Olmos-Serrano JL; Gallo V; Haydar TF J Neurodev Disord; 2019 Dec; 11(1):35. PubMed ID: 31839007 [TBL] [Abstract][Full Text] [Related]
15. Treatment with neuropeptides attenuates c-fos expression in a mouse model of fetal alcohol syndrome. Incerti M; Vink J; Roberson R; Abebe D; Spong CY Am J Perinatol; 2010 Oct; 27(9):743-8. PubMed ID: 20446212 [TBL] [Abstract][Full Text] [Related]
16. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts. Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335 [TBL] [Abstract][Full Text] [Related]
17. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313 [TBL] [Abstract][Full Text] [Related]
18. The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome. Stagni F; Uguagliati B; Emili M; Giacomini A; Bartesaghi R; Guidi S Sci Rep; 2021 Mar; 11(1):6300. PubMed ID: 33737521 [TBL] [Abstract][Full Text] [Related]
19. Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. Corrales A; Parisotto EB; Vidal V; García-Cerro S; Lantigua S; Diego M; Wilhem Filho D; Sanchez-Barceló EJ; Martínez-Cué C; Rueda N Behav Brain Res; 2017 Sep; 334():142-154. PubMed ID: 28743603 [TBL] [Abstract][Full Text] [Related]
20. Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse. Sari Y; Weedman JM; Nkrumah-Abrokwah M J Mol Neurosci; 2013 Jan; 49(1):150-6. PubMed ID: 23229836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]